Publications by authors named "Steven Averbuch"

Claim this Profile
M
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Steven Averbuch

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why Oncologists Should Care About Climate Change.
Joan H Schiller, Steven D Averbuch, Christine D Berg

JCO Oncol Pract· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.
Apostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, Steven D Averbuch, Daniel Chen

J Clin Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
Apostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, Steven D Averbuch, Daniel Chen

J Immunother Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying factors for the success of stratified medicine.
Mark R Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D Averbuch

Nat Rev Drug Discov· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating clinical trials into meaningful outcomes.
Patricia M LoRusso, Lowell E Schnipper, David J Stewart, Scott A Boerner, Steven D Averbuch

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
Patricia M LoRusso, Aparna B Anderson, Scott A Boerner, Steven D Averbuch

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Hui Huang, Jame Abraham, Elizabeth Hung, Steven Averbuch, Maria Merino

Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Michael Wolf, Helen Swaisland, Steven Averbuch

Clin Cancer Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giuseppe Giaccone, Roy S Herbst, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Steven D Averbuch

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Roy S Herbst, Giuseppe Giaccone, Joan H Schiller, Ronald B Natale, Vincent Miller, Steven D Averbuch

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.
Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi, Graham Richmond, Michael Hutchison, Steven Averbuch

Anticancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Karen Kelly, Steven Averbuch

Semin Oncol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of tyrosine kinase inhibitors in breast cancer.
Steven Averbuch, Mana Kcenler, Charles Morris, Alan Wakeling

Cancer Invest· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Mark G Kris, Ronald B Natale, Roy S Herbst, Thomas J Lynch, Diane Prager, Steven D Averbuch

JAMA· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
Steven D Averbuch

Clin Lung Cancer· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Steven Averbuch

J Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Patricia M LoRusso, Roy S Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Steven D Averbuch

Clin Cancer Res· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, Eric J Small, Eric H Rubin, Steven D Averbuch

J Clin Oncol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung cancer prevention: retinoids and the epidermal growth factor receptor-a phoenix rising?
Steven D Averbuch

Clin Cancer Res· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis